Research thatreshaped strategy.
Selected engagements from our Private Equity and Healthcare & Life Sciences practices. Methodology, sample, and outcomes disclosed. Client names held confidential.
Clinical urgency starts the conversation, finance controls every gate, coalition alignment closes the deal.
Switching intent is high. The product specification is non-negotiable.
Three behavioral segments. One clear target. The firmographic model was wrong.
API synthesis is the choke point. Raw-material geographic concentration is the systemic risk.
A vast majority see value. Buying group is collaborative, price lands within a well-defined band, timeline is 6 to 18 months.
A strong majority of physicians would move a portion of patients to the expanded-lead patch.
The trial-to-steady-state curve, mapped before commercial launch scaled.
The market is consolidating around incumbents. The growth window is liquid biopsy plus serial monitoring.
Hospital finance leaders want to consolidate, not supplement: a vast majority would replace existing RCM benchmarking tools.
Financial sustainability is the priority every other priority depends on.
Backbone selected, alternate dosing validated, and oncologist adoption modeled across multiple markets.
Multi-sourcing is the rule. The win is winning the second slot, not consolidating the first.